|
Marinomed Biotech AG / Key word(s): Insolvency Marinomed Biotech AG announces unanimous approval of the restructuring plan by creditors 14-Nov-2024 / 14:34 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Korneuburg, Austria, November 14, 2024 – Marinomed Biotech AG (VSE:MARI) announces that the creditors’ assembly unanimously approved the restructuring plan presented at the final court hearing at the Korneuburg Regional Court on November 14, 2024. The established quota is 30%, payable in several tranches within two years. 5% is to be deposited as a cash quota. The liquidity required for the repayment of the quotas is to be partially funded through the sale of the Carragelose business unit of Marinomed Biotech AG. A super quota of up to a further 7% will be distributed if milestone payments from the sale of the Carragelose business within two years exceed the planned amount. Confirmation of the restructuring plan and termination of the proceedings are subject, among other things, to the payment of the 5% cash deposit and a standstill declaration from the European Investment Bank (EIB). The Company will provide information on further developments.
+++ End of ad-hoc announcement +++ End of Inside Information 14-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
ArriVent prices $175M IPO in back-to-back oncology biotech listings
ArriVent Biopharma will join the Nasdaq on Friday morning in a strong start to biotech’s first batch of initial public offerings this year. The Pennsylvania
January 27, 2024